Baseline and mutagen-induced sister chromatid exchanges in lymphocytes of pharmacists handling anticancer drugs

Environmental Epidemiology and Toxicology

Volumn 2, Issue 4, 2000, Pages 254-260

  McDiarmid, Melissa A ^a   Kolodner, Ken ^b   Humphrey, Frances ^c   Putman, Donald ^d   Jacobson Kram, David ^d  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b Johns Hopkins Hospital ^*  (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d BioReliance   (United States)

Author keywords

Anticancer drugs; Pharmacists; Sister chromatid exchange

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; MESYLIC ACID ETHYL ESTER; MITOMYCIN C; MUTAGENIC AGENT; PHOSPHORAMIDE MUSTARD;

ADULT; ARTICLE; BIOLOGICAL MONITORING; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; FEMALE; GENETIC STABILITY; GENOTOXICITY; HUMAN; HUMAN CELL; LYMPHOCYTE; MALE; MUTAGEN TESTING; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HAZARD; PHARMACIST; PRIORITY JOURNAL; RISK ASSESSMENT; SISTER CHROMATID EXCHANGE;

EID: 0034470597     PISSN: 15227987     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. American Society of Hospital Pharmacists. Technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm 1990: 47: 1033-1049.
2. Au W.W., Sierra-Torres C.H., Cajas-Salazar N. Shipp B.K., and Legator M.S. Cytogenetic effects from exposure to mixed pesticides and the influence from genetic susceptibility. Environ Health Perspect 1999: 107: 501-505.
3. Au W.W., Wilkinson G.S., Tyring S.K., Legator M.S., El Zin R., Haliberg L., and Heo M.Y. Monitoring populations for DNA repair deficiency and for cancer susceptibility. Environ Health Perspect 1996: 104: 579-584.
4. Bochkov N.P., Filippova T.V., Kuzin S.M., and Srukolov S.V. Cytogenetic effects of cyclophosphamide on human lymphocytes in-vivo and in-vitro. Mutat Res 1986: 159: 103-107.
5. Brumen V., and Horvat D. Work environment influence on cytostatics-induced genotoxicity in oncology nurses. Am J Int Med 1996: 30: 67-71.
6. Chabner B.A. Second neoplasm - a complication of cancer therapy. N Engl J Med 1977: 297: 213-215.
7. Dearfield K.L., Jacobson-Kram D., Buenaventura S.K., and Williams J.R. In-vitro assays of in-vivo exposure to cyclophosphamide: Induction of sister-chromatid exchanges in peripheral lymphocytes, bone marrow cells and in cultured cells exposed to plasma. Mutat Res 1985: 158: 92-104.
8. deRatt W.K., Davis P.B., and Bakker G.L. Induction of sister-chromatid exchanges by alcohol and alcoholic beverages after metabolic activation by rat-liver homogenate. Mutat Res 1983: 124 (1): 85-90.
9. Dillehay L.E., Jacobson-Kram D., and Williams J.R. DNA topoisomerases and models for sister chromatid exchange. Mutat Res 1989: 215: 15-23.
10. Falck K., Grohn M., Sorsa M., et al. Mutagenicity in urine of nurses handling cytostatic drugs. Lancet 1979: i: 1250-1251.
11. Ferguson R., Everts R., Robbie M.A., Harvey V., Tempel D., Mak D., and Gerred A.J. The use within New Zealand of Cytogenetic approaches to monitoring of hospital pharmacists for exposure to cytotoxic drugs: Report of a pilot study in Auckland. Aust J Hosp Pharm 1988: 18: 228-233.
12. Finette B.A., Homans A.C., and Albertini R.J. Emergence of genetic instability in children treated for leukemia. Science 2000: 288: 514-517.
13. Fuchs J., Hengstler J.G., Jung D., et al. DNA damage in nurses handling antineoplastic agents. Mutat Res 1995: 342: 17-23.
14. Gebhart E., Windolph B., and Wopfner F. Chromosome studies on lymphocytes of patients under cytostatic therapy: II. Studies using the BUDR-labeling technique in cytostatic interval therapy. Hum Genet 1980: 56: 157-167.
15. Hoover R., and Fraumeni J.F., Jr. Drug-induced cancer. Cancer 1981: 47: 1071-1080.
16. International Agency for Research on Cancer. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans: some antineoplastic and immunosuppressive agents. Vol. 26. IARC, Lyon, France, 1981.
17. International Agency for Research on Cancer. IARC monographs on the evaluation of the carcinogenic risk of chemicals to human: pharmaceutical drugs. Vol. 50. IARC, Lyon, France, 1990.
18. Jacobson-Kram D., Albertini R.J., Brandda R.F., Falta M.T., Iype RT., Kolodner K., Liou S.-H., McDiarmid M.A., Morris M., Nicklas J.A., O'Neill J.P., Poirier M.C., Putman D., Strickland P.T., Williams J.R., and Xiao S. Measurement of chromosomal aberrations, sister chromatid exchange, HPRT mutations and DNA adducts in peripheral lymphocytes of human populations potentially at increased risk for cancer. Environ Health Perspect 1993: 101: 121-125.
19. Kato H. Possible role of DNA synthesis in formation of sister chromatid exchanges. Nature 1974: 252: 739.
20. Kim J.P., D'Arpa P., Jacobson-Kram D., and Williams J.R. Ultra-violet-light exposure induces a heritable sensitivity to the induction of SCE by mitomycin-C. Mutat Res 1985: 149: 437-442.
21. Lambert B., Ringborg U., Harper E., and Linblod A. Sister-chromatid exchanges in lymphocyte cultures of patients receiving chemotherapy for malignant disorders. Cancer Treat Rep 1978: 62: 1413-1419.
22. Latt S.A., Allen J., Bloom S.E., Carrano A., Falke E., Kram D., Schneider E., Schreck R., Tice R., Whitfield B., and Wolff S. A report of the gene-tox program. Mutat Res 1981: 87: 17-62.
23. Latt S.A., Schreck R.R., Loveday K.S., Dougherty C.P., and Shuler C.F. Sister chromatid exchanges. In: Harris H., Hirschornk (Eds.). Advances in Human Genetics, Vol. 10. Plenum, New York, 1980 p. 267.
24. Lundgren K., and Lucier G.W. Differential enhancement of sister-chromatid exchanges frequencies by a-naphthoflavone in cultured lymphocytes from smokers and non-smokers. Mutat Res 1985: 216: 307-308.
25. McDiarmid M.A., Strickland P.T., Kolodner K., Hansen J., and Jacobson-Kram D. Baseline and phosphoramide mustard-induced sister-chromatid exchanges in cancer patients treated with cyclophosphamide. Mutat Res 1990: 241: 273-278.
26. McDiarmid M.A., Kolodner K., Humphrey F., Putman D., and Jacobson-Kram D. Baseline and phosphoramide mustard-induced sister-chromatid exchanges in pharmacists handling anti-cancer drugs. Mutat Res 1992: 279: 199-204.
27. Meiying C., and Xianting Z. Comparative studies on spontaneous and mitomycin C-induced sister-chromatid exchanges in smokers and non-smokers. Mutat Res 1982: 105: 195-200.
28. Murnane J.P. Role of induced genetic instability in the mutagenic effects of chemicals and radiation. Mutat Res 1996: 367: 11-23.
29. Nevstad N.P. Sister-chromatid exchanges and chromosomal aberrations induced in human lymphocytes by the cytostatic drug adrimycin in vivo and in vitro. Mutat Res 1978: 57: 253-258.
30. Nguyen T.V., Theiss T.C., and Matney T.S. Exposure of pharmacy personnel to mutagenic antineoplastic drugs. Cancer Res 1982: 42: 4792-4796.
31. Norppa H., Sorsa M., Vainio H., et al. Increased sister-chromatid exchange frequencies in lymphocytes of nurses handling cytostatic drugs. Scand J Work Environ Health 1980: 6: 299-301.
32. Pina C.A., and Madrigal - Bujaidar E. SCE frequencies induced by ethanol, tequila and brandy in mouse bone marrow cells in vivo. Departamento de Morfologia, Escuela Nacional de Ciencias Biologicas, Mexico City, Mexico. Toxicol Lett 1993: 66 (1): 1-5.
33. Poirier M.C., Reed E., Ozols R.F., Fasy T., and Yaspa S. DNA adducts of cisplatin in nucleated peripheral blood cells and tissues of cancer patients. Prog Exp Tumor Res 1987: 31: 104-113.
34. Raposa T. SCE and chemotherapy of non-cancerous and cancerous conditions. In: Sandberg AA (Ed.), Sister Chromatid Exchanges. Progress and Topics in Cytogenetics, Vol. 2. Alan R. Liss, New York, NY 1982, pp. 579-617.
35. Sieber S.M., and Adamson R.H. Toxicity of antineoplastic agents in man: chromosomal aberrations, infertility effects, congenital malformations and carcinogenic potential. Adv Cancer Res 1975: 22: 57-155.
36. Stetka D.G., Wolff S. Sister-chromatid exchanges as an assay for genetic damage by mutagen carcinogens: I. In vivo test for compounds requiring metabolic activation. Mutat Res 1976: 41: 333-342.
37. Stiller A., Obe G., Boll I., and Pribilla W. No elevation of the frequencies of chromosomal alterations as a consequences of handling cytostatic drugs, analysis with peripheral blood and urine of hospital personnel. Mutat Res 1983: 121: 253-259.
38. Stolley P.A., Soper K.A., Galloway S.M., Nichols W.W., Norman S.A., and Wolman S.R. Sister-chromatid exchanges in association with occupational exposure to ethylene oxide. Mutat Res 1984: 129: 89-102.
39. Stucker I., Hirsch A., Doloy T., Bastie-Sigeac, and Hemon D. Urine mutagenicity, chromosomal abnormalities and sister-chromatid exchanges in lymphocytes of nurses handlings cytostatic drugs. Int Arch Occup Environ Health 1986: 57: 195-205.
40. Taylor J.H. Sister chromatid exchanges in tritium-labelled chromosomes. Genetics 1958: 43: 515.
41. Thiringer G., Granung G., Holmen A., et al. Comparison of methods for the biomonitoring of nurses handling antitumor drugs. Scand J Work Environ Health 1991: 17: 133-138.
42. Tucker J.D., Aulelta A., Cimino M.C., Dearfield K., Jacobson-Kram D., Tice R., and Carrano A.V. Sister chromatid exchange: Second Report of the Gene-Tox Program. Mutat Res 1993: 297: 101-180.
43. Tucker M.A., Coleman C.N., and Cox R.S. Risk of second cancers after treatment for Hodgkin's. N Engl J Med 1988: 318: 76-81.
44. Waksvik H., Kleep O., and Brogger A. Chromosome analyses of nurses handling cytostatic agents. Cancer Treat Rep 1981: 65: 607-610.